Lung Cancer

ASCO Endorses Lung Cancer Guidelines for Molecular Testing

ASCO has endorsed a clinical practice guideline from several associations on when to offer molecular testing for EGFR and ALK mutations in lung cancer patients.

Lung Cancer

The US Food and Drug Administration has granted orphan drug designation to tarextumab for the treatment of pancreatic cancer and small-cell lung cancer.

A study of nivolumab compared with docetaxel in patients with squamous cell NSCLC was stopped early after an analysis showed superiority of the study drug.

This one-act play features a patient, former smoker, navigating the CMS rules for lung cancer CT screening in a shared decision-making session with his doctor.

Experts from ASCO and AACR have penned a statement for policymakers on the potential negative effects of e-cigarettes and other nicotine-deliveries electronics.

Adding linifanib to a carboplatin/paclitaxel regimen improved progression-free survival over placebo in advanced non-squamous NSCLC patients.

An analysis showed that etoposide-cisplatin or carboplatin-paclitaxel with RT yielded similar survival in patients with stage III non-small-cell lung cancer.

The FDA has approved the combination of ramucirumab and docetaxel for the treatment of patients with metastatic non-small-cell lung cancer.


Subscribe to Lung Cancer on [sitename]

By clicking Accept, you agree to become a member of the UBM Medica Community.